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Can We Rely on the Dermatology Life Quality Index
as a Measure of the Impact of Psoriasis or Atopic
Dermatitis?
James Twiss1, David M. Meads1, Elizabeth P. Preston1, Sigrid R. Crawford1 and Stephen P. McKenna1
The Dermatology Life Quality Index (DLQI) is a widely used health-related quality of life measure. However,
little research has been conducted on its dimensionality. The objectives of the current study were to apply
Rasch analysis to DLQI data to determine whether the scale is unidimensional, to assess its measurement
properties, test the response format, and determine whether the measure exhibits differential item functioning
(DIF) by disease (atopic dermatitis versus psoriasis), gender, or age group. The results show that there were
several problems with the scale, including misfitting items, DIF by disease, age, and gender, disordered
response thresholds, and inadequate measurement of patients with mild illness. As the DLQI did not benefit
from the application of Rasch analysis in its development, it is argued that a new measure of disability related to
dermatological disease is required. Such a measure should use a coherent measurement model and ensure that
items are relevant to all potential respondents. The current use of the DLQI as a guide to treatment selection is
of concern, given its inadequate measurement properties.
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INTRODUCTION
The Dermatology Life Quality Index (DLQI; Finlay and Khan,
1994) is the most commonly used patient-reported outcome
measure in dermatology. It was designed to be a generic
dermatology health-related quality of life (HRQL) question-
naire and has been translated into 55 languages. The measure
has been used in many clinical studies in over 30 skin
conditions, but primarily in studies of psoriasis and atopic
dermatitis (AD; Lewis and Finlay, 2004; Basra et al., 2008). In
the United Kingdom, the DLQI is used to determine whether
patients are eligible to receive biological interventions for
psoriasis (Smith et al., 2005, 2009; NICE, 2008a, b, 2009).
Although the classical psychometric properties (including
test retest reliability, internal consistency, and construct
validity) of the questionnaire have generally been found to
be adequate, more detailed analyses using Rasch analysis
have highlighted several problems with the scale (Nijsten
et al., 2006a, 2007). Rasch analysis (Rasch, 1960) is now
seen as the method of choice for the development and
improvement of questionnaires as it has several advantages
over Classical Test Theory approaches such as factor analysis
(Wright, 1996; Wright and Tennant, 1996; Luquet et al.,
2001; Prieto et al., 2003; Tennant et al., 2004; Waugh and
Chapman, 2005; Nijsten et al., 2006a).
DLQI scores for individuals with different types of skin
conditions are often combined in research studies (Papoutsaki
et al., 2007; Schmitt et al., 2007; Potocka et al., 2008, 2009;
Quandt et al., 2008; Ludwig et al., 2009). Despite this, no
previous research has assessed whether it is justifiable to
combine DLQI data in this way. One way in which this can
be determined is by the use of differential item functioning
(DIF) analysis within the Rasch framework (Holland and
Wainer, 1993; Brodersen et al., 2010).
The aim of the present study was to reinvestigate the
scaling properties of the DLQI in combined samples of
psoriasis and AD patients. The study also investigated the
scaling properties of the DLQI in psoriasis and AD popula-
tions separately. The Rasch model was used to determine:
K whether the scale was unidimensional,
K the level of trait (HRQL) covered by the scale,
K how well items were targeted to the populations,
K whether the response categories were working in a
logical way,
K whether the DLQI was free from DIF by age and gender,
and
K whether it is justifiable to compare scores of psoriasis and
AD samples using the DLQI.
RESULTS
Demographic details of the samples are shown in Table 1.
The two samples were well matched in terms of age and
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gender. AD patients had had their condition for longer
(Po0.001). DLQI scores were higher for the psoriasis group
(Po0.001), which also reported worse perceived general
health (P¼ 0.001) and perceived illness severity (P¼0.018).
Item frequencies
DLQI raw score item responses for the combined samples are
shown in Figure 1. The figure indicates how frequently each
item response was used. A high proportion of participants
responded ‘‘not relevant’’ to items 6, 7, and 9.
Rasch analysis
The initial likelihood ratio test, used to determine the most
appropriate Rasch model, was statistically significant, sup-
porting the use of the partial credit model for the analyses
(Po0.001).
Rasch analysis of the combined sample—initial run
Initial overall scale fit. Table 2 shows the Rasch overall
fit statistics for the combined sample. The DLQI misfit the
Rasch model (item–trait interaction, P¼0.010). This confirms
that the DLQI does not form a unidimensional measure
of health-related quality of life (HRQL) for combined
psoriasis and AD samples. In addition, the mean item
residual statistic was low and further indicative of misfit to
the Rasch model. This suggests that there are problems with
individual items in the scale. The Person Separation Index
(PSI) indicated that the DLQI had adequate internal reli-
ability. One pair of items (items 1 and 6; see item descriptions
listed in Table 3) had a high residual correlation (0.312),
suggesting a response dependency between the items. In this
case, answers to one item had too strong an association to
answers to the other.
Initial item fit. Table 3 reports the fit statistics for the items in
the DLQI. Items 2 (P¼ 0.005), 5 (P¼0.013), and 7
(P¼0.013) showed misfit to the model. Item 5 also had a
low-fit residual (o2.5), suggesting that it was redundant.
Differential item functioning. Table 3 also shows the items
with significant DIF. Figure 2 illustrates the DIF by disease
found for item 7. It plots the observed item characteristic
curve for both disease groups on the same logit scale and
against the predicted ‘‘S’’-shaped curve. At every level of
severity from left to right (mild to severe), AD patients were
more likely to affirm the item, indicating that the item works
differently in each disease.
Item response thresholds. Response thresholds were dis-
ordered for items 4, 6, 7, 8, and 9, showing that the response
formats for these items did not work logically. Further investi-
gation of these showed that response options 2 (‘‘a lot’’) and
3 (‘‘very much’’) were disordered for items 4, 7, and 8.
Response options 1 (‘‘a little’’), 2 (‘‘a lot’’), and 3 (‘‘very
much’’) were disordered for items 6 and 9, indicating that a
dichotomous response format would be more appropriate for
these two items.
Item locations and logit coverage. The DLQI item map for
the combined sample is shown in Figure 3. The location of
each person and each item response on the same logit scale is
illustrated. The map shows that items are bunched around the
middle of the logit scale, and that there are few items
covering the mild end. This indicates that the scale does
not work well with individuals who have mild disease. For
example, the scale would not be able to show improve-
ments in scores for patients with milder disease who benefit
from treatment. The map also shows some redundancy in
the scale.
Table 1. Sample characteristics
Psoriasis
(n=146)
Atopic dermatitis
(n=146)
Gender (%)
Male 73 (50.0) 73 (50.0)
Female 73 (50.0) 73 (50.0)
Age (years)
Mean (SD) 44.4 (14.7) 45.5 (16.6)
Range 66.0 (17.0–83.0) 62.0 (20.0–82.0)
Duration (years)
Mean (SD) 20.9 (13.5) 28.2 (17.5)
Range 67.0 (2.0–69.0) 76.0 (0.0–76.0)
Perceived general health (%)
Excellent 16 (11.0) 15 (10.3)
Good 68 (46.6) 96 (65.8)
Fair 44 (30.1) 32 (21.9)
Poor 17 (11.6) 3 (2.1)
Perceived illness severity (%)
Mild 38 (26.0) 60 (41.1)
Moderate 57 (39.0) 57 (39.0)
Quite severe 43 (29.5) 26 (17.8)
Very severe 6 (4.1) 3 (2.1)
DLQI score
Mean (SD) 29.2 (22.3) 20.7 (16.7)
Median (IQR) 23.3 (10.0–40.8) 15.5 (10.0–26.7)
Range 96.7 (0.0–96.7) 86.7 (0.0–86.7)
Marital status (%)
Married/living as 89 (61.0) 95 (65.1)
Single 57 (39.0) 50 (34.2)
Abbreviations: DLQI, Dermatology Life Quality Index; IQR, interquartile
range.
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Rasch analysis of the combined sample—refinement of the scale
Several changes were made to the scale in an attempt to
improve its measurement properties. The effects of the
changes to the scale are summarized in Table 2.
In Analysis 2, participants showing misfit to the model
were removed. This made little change to the overall model
fit and the scale continued to show the problems identified in
the first analysis. In Analysis 3, responses of ‘‘a lot’’ and ‘‘very
much’’ were combined for items 4, 6, 7, 8, and 9 to correct
for the problems with these responses. This resulted in a
marginal improvement in the overall scale fit statistics and the
response problems for items 4, 7, and 8 were resolved.
However, response problems remained for items 6 and 9. It
appeared that a dichotomous response format would be more
appropriate for these two items. Consequently, for Analysis 4,
the responses ‘‘a little’’, ‘‘a lot’’, and ‘‘very much’’ were
combined for items 6 and 9. Overall fit statistics again
improved marginally. The measure continued to show
problems related to item misfit and DIF by age, gender, and
disease. In particular, item 2 continued to show significant
misfit (P¼0.007). This item was deleted for Analysis 5, which
actually caused the overall fit statistics for the scale to
deteriorate. Therefore, item 2 was reinstated.
For Analyses 6 and 7, the items showing the greatest level
of DIF were split. In Analysis 6, items 4 and 7 were split in
order to become separate items for psoriasis and AD patients
(as they exhibited DIF associated with disease). In Analysis 7,
item 10 (where there was DIF by age) was also split.
Following Analysis 7, the overall fit statistics for the DLQI
were improved. Despite this, the item fit residuals suggested
that there were continuing problems with the items. Item 2
continued to show misfit to the model (P¼ 0.009), and
several items continued to show low-level DIF by age,
gender, and disease. Furthermore, these changes were unable
to overcome the problems associated with the scale’s poor
coverage of mild impairment.
Table 2. Rasch analysis overall fit statistics
Items Persons
Sample
Analysis
number Description n
Item–person
interaction PSI Mean SD Mean SD
Combined Analysis 1 All of sample 282 0.010 0.85 0.81 0.98 0.30 0.81
Combined Analysis 2 Delete two misfitting participants 280 0.011 0.79 0.86 0.97 0.30 0.76
Combined Analysis 3 Collapse responses 2 and 3 for items 4, 6, 7, 8, and 9 280 0.040 0.72 0.79 0.88 0.28 0.78
Combined Analysis 4 Collapse responses 2, 3, and 4 for items 6 and 9 279 0.063 0.78 0.72 0.80 0.27 0.83
Combined Analysis 5 Delete item 2 279 0.021 0.72 0.89 0.85 0.30 0.81
Combined Analysis 6 Reinstate item 2 and split items 4 and 7 by disease 279 0.076 0.78 0.60 0.75 0.27 0.82
Combined Analysis 7 Split item 10 by age 279 0.185 0.78 0.56 0.75 0.27 0.83
Psoriasis Analysis 1 All of sample 141 0.005 0.82 0.23 0.92 0.24 0.85
Atopic dermatitis Analysis 1 All of sample 141 0.460 0.63 0.64 0.66 0.30 0.78
Abbreviation: PSI, Person Separation Index.
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*Item 7 is a two-part question, it first asks whether work or study has been prevented 
(yes/no) and then (if ‘No’) to what degree the skin condition has been a problem at 
work/study (‘A lot’, ‘A little’, or ‘Not at all’). If participants answer ‘Yes’ to the first part 
of the question they are scored the same as ‘Very much’.
Figure 1. Dermatology Life Quality Index (DLQI) raw-score item frequencies. This shows the percentage of patients who responded with each response option
for each question of the DLQI. Information is based on the raw scores.
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Rasch analysis of the psoriasis and AD samples separately
Further analyses were conducted to assess whether the DLQI
fit the Rasch model for the psoriasis and AD samples
separately. Overall fit statistics for the two samples are
shown in Table 2.
Psoriasis
Fit statistics showed that the DLQI scores for the
psoriasis sample misfit the Rasch model (item–trait inter-
action¼ 0.005). Thus, the DLQI was not a unidimensional
measure of HRQL for this sample. The PSI was 0.82, and this
showed the scale to have adequate levels of internal
reliability. Investigation of the individual item fit showed
that item 2 (Po0.001) and item 7 (P¼ 0.037) misfit the
Rasch model. Items 6–9 had disordered response thresholds.
Items 2 (P¼0.003), 4 (P¼ 0.033), and 6 (P¼ 0.047) showed
significant uniform DIF by gender, and items 2 (P¼0.009), 4
(P¼0.050), and 8 (P¼ 0.020) exhibited significant nonuni-
form DIF by gender. Items 5 (P¼0.040) and 10 (P¼0.002)
showed uniform DIF by age. Items were again clustered at the
center of the HRQL spectrum with too few mild items.
Atopic dermatitis
The overall fit statistics showed that the DLQI fit the Rasch
model for the AD patients (item–trait interaction¼0.460).
Despite this, several problems with the measurement proper-
ties of the scale were identified. The PSI was low, indicating
that the scale did not have adequate internal reliability. In
addition, the item residual statistics were indicative of misfit
to the Rasch model, suggesting problems with the items. A
single item (item 4, P¼0.048) showed misfit to the model.
Items 2 and 4–8 had disordered response thresholds. The
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Figure 2. Differential item functioning by disease for work/study item. This shows the item characteristic curve (ICC) for item 7 of the Dermatology Life Quality
Index. In Item Response Theory, an ICC describes the relationship between a latent ability and the performance on a test item. The curved line represents the
expected scores for this item. The actual scores for the item are shown for psoriasis and atopic dermatitis patients separately.
Table 3. Individual item fit statistics and DIF
Item description Location Fit residual v2 P-value Uniform DIF Non-uniform DIF
(1) Itchy, sore, painful, or stinging 1.61 0.03 3.38 0.496 Disease (P=0.04)
(2) Embarrassment/self-consciousness 0.52 1.97 15.00 0.005 Age group (P=0.003)/
gender (P=0.010)
(3) Interferes with shopping/looking
after home/garden
0.99 1.18 3.75 0.441 Disease (P=0.008) Disease (P=0.03)
(4) Influences choice of clothes 0.54 0.14 4.43 0.350 Gender (P=0.002)/
disease (P=0.014)
(5) Affects social/leisure activities 0.32 2.69 12.73 0.013 Disease (P=0.025)
(6) Affects ability to do sports 0.02 0.29 3.00 0.558 Gender (P=0.006) Gender (P=0.009)
(7) Prevents working/studying 0.25 0.23 12.59 0.013 Gender (P=0.007)/
disease (Po0.001)
(8) Creates problems with partner/close
friends/relatives
0.59 0.89 2.12 0.715
(9) Causes sexual difficulties 0.89 1.23 2.20 0.698
(10) Problem with treatment 0.36 0.47 3.48 0.481 Age group (Po0.001)
Abbreviation: DIF, differential item functioning.
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response thresholds were also poorly defined in the
other items, suggesting that a complete restructuring of
the response options is necessary. Items 4 (P¼ 0.010) and
7 (P¼ 0.043) showed uniform DIF by gender, and item
6 (P¼0.012) exhibited nonuniform DIF by gender. Items 2
(P¼0.010), 4 (P¼0.020), 7 (Po0.001), and 10 (P¼0.028)
showed uniform DIF by age, and item 7 (o0.001) showed
nonuniform DIF by age. Items were again clustered at the
center of the HRQL spectrum with too few mild items.
DISCUSSION
A growing number of studies are using Rasch analysis to
assess the measurement properties of widely used HRQL
measures, such as the SF-36 and the Hospital Anxiety and
Depression Scale (Raczek et al., 1998; Smith et al., 2006;
Dallmeijer et al., 2007; Pallant and Tennant, 2007). Review
of these studies shows that there are often significant
problems with the scales, and that several changes would
be necessary to improve their measurement properties.
Where significant problems are found, this indicates that
the scales are not valid in their standard format and may only
produce valid scores after the raw scores have been
transformed using Rasch analysis. Researchers should con-
sider carefully before making substantial changes to existing
measures, as this may violate the theoretical structure of the
scale and detract from the developers’ intentions that the
scales should be simple to use and score.
Fit to the Rasch model for the combined sample
To our knowledge, no previous study has assessed the
measurement properties of the DLQI in both psoriasis and AD
populations. The study found that the DLQI failed to meet
fundamental measurement requirements, indicating that it
does not measure a single unidimensional construct. As a
consequence, total scores on the measure do not provide
valid information about the respondent.
Although the internal reliability (as indicated by the PSI) of
the DLQI was good, several problems with the measurement
properties of the scale were identified. Three items misfit the
Rasch model, indicating that respondents were not answering
these items in the way the model would predict. DIF analysis
showed that several items showed DIF associated with age,
gender, and/or disease. The evidence of DIF by disease
indicates that DLQI scores for patients with psoriasis and AD
should not be compared. In addition, scores for these
different patient groups should not be combined during
clinical trials or research studies.
Too few items covered the mild end of the measurement
scale, indicating that the DLQI will not be responsive to
change in individuals with mild disease. Response thresholds
were disordered for five items and poorly defined for the
remainder. The greatest source of disorder resulted from the
response options ‘‘a lot’’ and ‘‘very much’’. Patients clearly
had difficulty distinguishing between these categories that are
conceptually similar. Item frequencies also showed that large
proportions of the samples answered ‘‘not relevant’’ to
several items. ‘‘Not relevant’’ responses are given the same
score as the ‘‘not at all’’ response, according to the DLQI
scoring guidelines (Finlay and Khan, 1994). This scoring
method presents a problem as individuals who responded
‘‘not relevant’’ may actually have had severe illness. Future
research using Rasch analysis is needed to investigate the
impact of this anomaly.
Overall fit to the Rasch model during refinement
Several changes were made to the DLQI in an attempt to
improve the measurement properties of the scale. An
acceptable level of fit to the model was eventually achieved
in Analysis 7 after substantial changes had been made. These
included altering the response options for 5 of the 10 items,
and splitting 3 of the items in order to reduce the levels of
DIF. Although this produced the best compromise, some
problems with the measurement properties of the scale
remained. The item fit residuals still indicated that there were
problems with the items, which appeared to be caused by the
misfit of item 2 and low-level DIF by age and/or gender and/
or disease in several items. Furthermore, there were still too
few items measuring mild illness. As several major changes to
the scale were required to improve its measurement proper-
ties, it is clear that the DLQI does not provide valid
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Figure 3. Logit scale. In Rasch analysis, the level of difficulty of items and the
ability of persons are measured using the logit scale. The figure shows the logit
position of each item response and the logit position of each person.
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measurement. It is also likely that additional DIF would arise
from using the measure with patients who have different
types of skin disease. Analysis of responses to the measure
would also become unwieldy, negating the developers’
intention that the scale should be short and easy to apply.
Fit to the Rasch model for the separate psoriasis and AD
samples
The DLQI misfit the Rasch model for the psoriasis sample,
indicating that it does not measure a unidimensional
construct for psoriasis patients. The DLQI did fit the Rasch
model for the AD sample, but showed several measurement
problems. Similar problems were identified for the two
groups separately as with the combined sample. This
indicated that both disease groups contributed to the misfit
to the Rasch model of the overall sample. In both diseases,
items misfit the Rasch model and exhibited DIF, response
thresholds were disordered, and there were too few mild
items. Although the DLQI did fit the Rasch model for the AD
group, the measurement properties of the scale were still
poor. For example, the internal reliability (PSI) for the
measure was poor, and the item residual statistics indicated
that there were problems with the items. In addition, 6 of the
10 items for the AD sample had disordered response
thresholds, and a complete restructuring of the response
format seemed appropriate.
The results of this study support two previous studies that
investigated the scaling properties of the DLQI using Rasch
analysis (Nijsten et al., 2006a, 2007). The first study found
that the DLQI misfit the Rasch model for both psoriasis and
AD samples. Both studies identified problems with individual
items in terms of misfit, DIF by age and gender, problems
with the response format, and with the measurement range of
the questionnaire. The second study also investigated the
cross-cultural equivalence of the DLQI using DIF analysis.
This study involved 450 patients with psoriasis from five
European countries and the United States. Results showed
that the DLQI misfit the Rasch model for the combined-
country data and for three of the countries separately. In
addition, each of the 10 items in the DLQI showed DIF by
country, indicating that the DLQI was working differently in
each country and that, consequently, international clinical
trial data should not be combined.
A previous study, using confirmatory factor analyses,
reported that the items in the DLQI form a higher-order
unidimensional factor for psoriasis patients (Mazzotti et al.,
2005). However, insufficient detail regarding model fit
statistics for the individual items was provided, making
meaningful comparisons with the present study difficult. The
detailed analyses of the present study have shown several
problems with the scale beyond the simple question of
overall fit to the model. The advantages of the Rasch model
over other approaches (such as factor analysis and two-
parameter Item Response Theory models) have been dis-
cussed in detail (Wright, 1996; Prieto et al., 2003; Andrich,
2004; Tennant et al., 2004; Waugh and Chapman, 2005).
It is likely that the problems identified with the DLQI are
due to in-built scale development weaknesses. During the
development of the DLQI, an overarching aim was to
develop a scale that would fit on one side of paper (Finlay
and Khan, 1994). Although this means that the DLQI is
short and easy to administer, this resulted in a scale
that was unable to measure the full range of HRQL impact
associated with dermatological disease. Many of the items
are also ambiguous in nature. Several include two or more
ideas in the same question, forming ‘‘double-barreled’’
questions. For example, item 3 asks how the patient’s skin
has interfered with ‘‘shopping’’, looking after the ‘‘home’’, or
‘‘garden’’. With such an item, patients may respond to
different parts of the question. This causes problems for the
measure as the different parts of the question represent
different levels of difficulty. Researchers have noted
the relation between double-barreled questions and DIF
(Hambleton, 2006). In addition, the phraseology of some of
the items, e.g., ‘‘leisure activities’’, is likely to present
problems for some respondents.
Alternative measures for health outcome assessment in
dermatological conditions are available, which have been
developed with the benefit of Rasch analysis. A subset of the
items in the Skindex (the Skindex-17) form a generic
dermatological measure that includes unidimensional
measures of psychosocial functioning and symptoms (Chren
et al., 1997; Nijsten et al., 2006b). Two other disease-specific
QoL measures are also available. The Psoriasis QoL scale
(McKenna et al., 2003) and the Quality of Life Index for Atopic
Dermatitis (Whalley et al., 2004) are unidimensional measures
of QoL that used the needs-based QoL model (Hunt and
McKenna, 1992) and were developed using Rasch analysis.
These latter two measures are disease specific and assess
a different outcome from the DLQI (QoL rather than HRQL).
Strengths and limitations of the study
This is one of the first studies to report on the Rasch analysis
of the DLQI, and, to our knowledge, the investigation of the
equivalence of the DLQI for different dermatological condi-
tions is previously unreported. Study data were derived from
two separate samples: psoriasis and AD. The psoriasis sample
was recruited from hospital records, whereas the AD sample
was identified through a self-help organization. The different
sampling methods are dealt with within the Rasch frame-
work, which is sample independent, as all patients are
measured on the same underlying construct. For the analyses
of DIF by dermatological condition, patients with the same
level of the underlying construct (HRQL impairment) are
compared, rather than comparing the two complete samples.
The total sample of 292 provided an excellent number for
Rasch parameter estimates as it was large enough to give 99%
confidence that the parameter estimates were within half a
logit of the stable value (Linacre, 1994). The two separate
samples (n¼141) provided 95% confidence that the esti-
mates were within half a logit of the stable value.
This study illustrated the use of the DLQI with psoriasis,
AD and combined psoriasis, and AD samples only. The DLQI
is also used with several other dermatological conditions and
further research could determine whether the scale works
adequately with such conditions.
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Conclusions
The DLQI has been described as a first-generation HRQL
measure in dermatology as it was developed without the
benefit of modern Item Response Theory techniques (Nijsten
et al., 2007). The fact that the DLQI has several measurement
problems is therefore not surprising. It is recommended that a
new measure of functional limitations in dermatology be
developed, which benefits from modern scaling techniques.
The DLQI should not be used to compare scores of psoriasis
and AD patients on the basis of the findings of the current
study. It may also not be valid to compare scores for groups
of patients whose profile differs in terms of age or gender.
The use of the DLQI for deciding which patients should
receive biological treatments in the United Kingdom is of
concern, given the lack of support for the measurement
properties of the scale.
MATERIALS AND METHODS
Design and data
Rasch analyses were based on two available data sets. AD and
psoriasis patients in the United Kingdom completed the DLQI in
postal surveys used to validate new psoriasis (Psoriasis QoL;
McKenna et al., 2003) and AD (Quality of Life Index for Atopic
Dermatitis; Whalley et al., 2004) quality of life questionnaires. The
psoriasis sample was recruited from the Manchester Psoriasis Service
database at Salford Royal Hospital, Greater Manchester, UK. The AD
sample was recruited through the National Eczema Society. The
original AD sample included 202 females (70.6%) and 84 males
(29.4), but a random sample (generated via SPSS 16 random sample
selection generator) of 73 males and 73 females was selected to
match the number of males and females in the psoriasis sample. This
was because uneven sample sizes can distort analysis of variance
analyses used for the investigation of DIF (Wright and Tennant,
1996; Hambleton, 2006). Information was collected describing
patient’s duration of illness, marital status, self-perceived general
health (very good/good/fair/poor), and self-perceived disease severity
(mild/moderate/quite severe/very severe).
Rasch analyses were conducted on the overall group and then on
the psoriasis and AD sample separately.
Dermatology Life Quality Index
The DLQI is a self-report 10-item questionnaire assessing the impact
of skin disease on the patient over the previous week. The items
cover symptoms, treatment, activity limitations, and emotional
reactions to having a skin disease. Nine items have four response
options: ‘‘Not at all’’, ‘‘A little’’, ‘‘A lot’’, and ‘‘Very much’’, whereas
item 7 first asks whether work or study has been prevented and then
(if ‘‘No’’) to what degree the skin condition has been a problem at
work/study (‘‘A lot’’, ‘‘A little’’, or ‘‘Not at all’’). Eight of the items
also have a ‘‘Not relevant’’ option that is scored ‘‘0’’, indicating no
problem. Individual item scores are summed to derive a total DLQI
score that can range from 0 to 30, with higher scores indicating
worse HRQL.
Analysis
Demographic information. Tests were conducted to compare the
AD and psoriasis samples in terms of their length of illness
(Mann–Whitney U-test), DLQI scores (Man–Whitney U-test), general
health (w2 analysis), and perceived illness severity (w2). Non-
parametric statistical analyses were conducted throughout because
of the non-normal distribution/ordinal nature of the data.
Item frequency analysis. Item response frequencies were
investigated before the data were Rasch analyzed.
Rasch analysis. The Rasch model is a simple logistic latent
trait Item Response Theory model. Rasch analysis places response
data for each individual and each item on the same spectrum of
severity (logit scale). According to the model, the probability
that an individual will respond in a certain way to a particular
item is a logistic function of the relative distance between the item
location (parameter) and the person location (parameter), and only
a function of these two factors. Persons and items are plotted on
the same logit scale on the basis of the difference in their location
on the underlying spectrum. This difference governs the probability
of the expected response for a person, of a given severity, on a
question of a given severity. If the observed data do not deviate
significantly from the expected responses, then the items fit the
Rasch model.
Rasch analysis also provides the opportunity to assess the
measurement properties of a questionnaire in a number of additional
ways:
K Where questionnaire items have more than two response
options, Rasch analysis allows the functioning of the response
format to be examined.
K As Rasch analysis also places each individual and each item
on the same logit spectrum, information is provided on the
order of each item in terms of its severity (and therefore
the relative impact of the item in terms of, say, HRQL impact)
and whether the items as a whole are well targeted to
respondents.
K DIF represents instability in the order of severity of items and
indicates that the scale may not work in the same way in subgroups
of individuals (for example, diagnosis subgroups, age, or gender)
who share the same level of trait being measured (Holland and
Wainer, 1993). Uniform DIF occurs when one group is more or
less likely to affirm an item at each level of severity. Nonuniform
DIF occurs when there is inconsistency in which group is more
likely to affirm an item for different levels of severity.
The Rasch Unidimensional Measurement Model 2020 (Andrich
et al., 2005) program was used for the analyses.
Analyses conducted were consistent with published guidelines
(Tennant and Gonaghan, 2007). Before analyses were conducted, it
was necessary to determine whether the rating scale (Andrich, 1978)
or partial credit model (Masters, 1982) was most appropriate. Both of
these approaches use the Rasch model, but differ slightly in their
mathematics. The rating scale model is more stringent in its
requirements as the distance between response thresholds has to
be uniform across all items. The likelihood ratio test is used to
identify the most appropriate model.
Internal reliability was analyzed using the PSI. The PSI is
indicative of the power of the construct to distinguish among
respondents. A PSI score of 0.70 is the minimum acceptable level.
The overall scale fit to the model was examined by reference to the
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overall item–trait interaction w2-fit value. A significant w2-statistic
(Po0.05) indicates that there is a real deviation of the scale from the
expected pattern and a lack of fit to the Rasch model. Overall fit of
the data is also investigated via Item and Person interaction statistics.
These assessments measure the extent to which observed item and
person estimates deviate from the expected. The mean location of the
items is always anchored at 0. Within this function, both Person fit
residual and Item fit residual statistics are transformed by Rasch
Unidimensional Measurement Model to approximate a Z-score; this
represents a standardized normal distribution. Therefore, when the
data fit the model, the overall distribution statistics for Item fit and
Person fit should have a mean ofB0 and a standard deviation ofB1.
Individual item fit statistics were also investigated via w2-fit
statistics. A significant w2-fit statistic (Po0.05) indicated misfit to the
model. Individual item fit residuals were also consulted. These
should fall within ±2.5 if all individuals responded in the
anticipated way. High negative residuals were indicative of overfit
to the scale (item redundancy), and high positive residuals were
indicative of misfit to the scale (low association with the scale score).
The functioning of the response options was investigated via
response thresholds. The thresholds represent the borders between
adjacent ordinal response options and should increase in a logical
way. If response options are disordered, the response categories are
not working in the intended way.
An analysis of variance of standardized residuals was carried out
to examine DIF by gender (males vs females), age group (below the
median age vs median age and above), and disease (AD versus
psoriasis). If the analysis of variance P-value was o0.05, then that
item was considered to exhibit DIF.
Targeting of the items to respondents was assessed by examining
the item map. These show the ordering of both persons and items on
the same logit scale and indicate whether the items in the scale are
well matched to the respondents.
If a scale is unidimensional, it should be free from item
dependency: similarity in items such that answers to one item have
too strong an influence over answers to other items (Tennant and
Gonaghan, 2007). This is assessed by inspecting the residual
correlation matrix for pairs of items with correlations exceeding 0.3.
Refinement of the measure
Rasch analysis can be used in an attempt to correct for problems
with the measurement properties of a scale. The following
approaches can be taken:
K Individuals that misfit the Rasch model (fit residuals4±2.5) can
be removed, as these cases do not respond in a way predicted by
the model.
K The response options can be altered by collapsing thresholds
between adjacent response options if they are working
incorrectly.
K Items can be deleted if they misfit the Rasch model.
K Items exhibiting uniform DIF can be split to allow them to have
different parameters for each group (for example, males and
females in the case of DIF by gender). Essentially, this method
allows an item to become two separate items with different item
locations.
The present study attempted to improve the measurement
properties of the DLQI by applying these methods.
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